State Street Corp Purchases 119,936 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

State Street Corp grew its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 9.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,452,811 shares of the company's stock after acquiring an additional 119,936 shares during the period. State Street Corp owned 5.05% of Krystal Biotech worth $264,455,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Key Financial Inc bought a new stake in shares of Krystal Biotech during the second quarter valued at approximately $28,000. Blue Trust Inc. increased its stake in Krystal Biotech by 2,328.6% during the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company's stock valued at $30,000 after purchasing an additional 163 shares in the last quarter. Values First Advisors Inc. acquired a new position in Krystal Biotech during the third quarter worth $53,000. Quest Partners LLC acquired a new position in Krystal Biotech during the second quarter worth $71,000. Finally, GAMMA Investing LLC grew its holdings in shares of Krystal Biotech by 184.8% during the third quarter. GAMMA Investing LLC now owns 430 shares of the company's stock valued at $78,000 after buying an additional 279 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

Analyst Ratings Changes

KRYS has been the topic of a number of analyst reports. Stifel Nicolaus upped their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a "buy" rating in a report on Wednesday, September 11th. Citigroup upped their price target on Krystal Biotech from $204.00 to $206.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. William Blair upgraded Krystal Biotech to a "strong-buy" rating in a research note on Friday, August 30th. HC Wainwright reiterated a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Tuesday. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Krystal Biotech in a research report on Thursday, August 29th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Krystal Biotech has an average rating of "Buy" and an average target price of $202.29.

Krystal Biotech Stock Up 0.7 %

NASDAQ KRYS traded up $1.38 during trading hours on Wednesday, reaching $187.12. 160,512 shares of the company were exchanged, compared to its average volume of 321,162. The stock has a market capitalization of $5.38 billion, a P/E ratio of 104.94 and a beta of 0.80. Krystal Biotech, Inc. has a 1 year low of $103.83 and a 1 year high of $219.34. The business's 50 day simple moving average is $181.31 and its 200-day simple moving average is $184.78.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.84 by $0.07. The business had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. Krystal Biotech's revenue for the quarter was up 879.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.67) earnings per share. As a group, sell-side analysts anticipate that Krystal Biotech, Inc. will post 2.97 earnings per share for the current year.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now owns 1,500,882 shares of the company's stock, valued at approximately $296,814,424.32. The trade was a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 14.10% of the company's stock.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).